Greenwich LifeSciences has secured approximately USD 2.5 million in private placement via a securities purchase agreement with its CEO. The transaction includes the sale and purchase of 174,825 shares at USD 14.30 per share.
The proceeds will be used for clinical development and supporting the company's working capital.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of immunotherapies aimed at preventing breast cancer recurrences. The company's primary candidate, GP2, is derived from the HER2/neu protein and is designed to target and prevent the recurrence of breast cancer in patients who have undergone surgery. GP2 has demonstrated promising results in a Phase IIb clinical trial and is currently being evaluated in the Flamingo-01 Phase III clinical trial.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.